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Human immunodeficiency virus (HIV) evolves with extraordinary rapidity. However, its evolution is
constrained by interactions between mutations in its fitness landscape. Here we show that an Ising model
describing these interactions, inferred from sequence data obtained prior to the use of antiretroviral drugs, can be
used to identify clinically significant sites of resistance mutations. Successful predictions of the resistance sites
indicate progress in the development of successful models of real viral evolution at the single residue level and
suggest that our approach may be applied to help design new therapies that are less prone to failure even where
resistance data are not yet available.
DOI: 10.1103/PhysRevE.93.022412
I. INTRODUCTION
Under selective pressure from suboptimal antiretroviral
treatment regimens, HIV has been observed to evolve drug
resistance within weeks of treatment initiation [1]. While
modern combination therapies have greatly reduced the rate
of evolution of drug resistance, resistant strains are found in
greater than 14% of newly infected patients in the United
States [2,3]. The rapid evolution of resistance is congruent
with the overall observation that HIV evolution is remarkably
fast, with studies indicating that in the absence of treatment a
single patient’s HIV infection will explore every possible point
mutation many times daily [4–6]. However, empirical studies
of viral sequence data indicate that HIV evolution is structured
and exhibits reproducible patterns [1,7].
The existence of significant correlations in the evolution of
HIV suggests that sequence data can be used to parametrize
statistical mechanical models of HIV evolution that predict
important features of its evolution, including the evolution
of drug resistance. Previous researchers have used a variety
of approaches to predict HIV fitness and aspects of its
evolution using viral sequence data on its own [7,8] and with
additional phenotypic properties such as drug resistance and
replicative capacity [9]. Others have addressed the problem of
predicting the sites of drug resistance mutations by detecting
sites under positive selection during treatment [10], supervised
learning [11], and structural modeling of protein-drug interac-
tions [11,12].
Here we use HIV sequence data from 757 unique patients,
obtained prior to the widespread clinical use of protease
inhibitors, to parametrize a spin representation of the stan-
dard Eigen model of quasispecies evolution [13–15] (see
Appendix A for details). This data was obtained from the
Los Alamos National Laboratory HIV sequence database
(www.hiv.lanl.gov). We then use the inferred model to predict
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sets of sites in HIV protease where joint mutations are
unlikely to significantly impair viral fitness. We hypothesize
that such sites are more likely to be sites of clinically relevant
drug resistance mutations because resistance mutations that
severely impair viral replication are unlikely to be selected.
The exclusion of sequence data obtained after the clinical
use of antiretroviral drugs limits the influence of selection
for drug resistance, which may be present even in sequences
obtained from drug-naive individuals (for example due to
transmitted drug resistance), and focuses instead on intrinsic
fitness constraints. Thus, our successful identification of major
drug resistance sites (defined in [16]) here suggests that our
techniques could be applied to predict HIV evolution in
response to new treatment regimens or vaccine candidates.
We note, however, that this identification of resistance sites
is “indirect” in the sense that only information about fitness is
used. Thus, these predictions are not specific to a particular
drug, and would be most useful in cases when resistance
information is unknown. In order to make highly accurate,
drug-specific predictions of resistance, additional information
would be required to narrow down the list of potential drug
resistance sites identified based on fitness constraints to the
ones that are most relevant for a particular case.
II. FITNESS AND PREVALENCE LANDSCAPES FROM
THE EIGENMODEL
We begin by inferring an estimate of the probability
distribution of mutations in the viral protease from sequence
data. Protease amino acid sequences are first translated into
a binary form, with the amino acid at each site i encoded by
si ∈ {0,1}, where 0 (1) denotes a wild type (mutant) amino
acid at that site. Full sequences are thus represented as vectors
s = (s1,s2, . . . ,sL), with L = 99 for protease. We assume that
the joint distribution of mutations is adequately captured by
the moments 〈sisj 〉 and find the maximum entropy distribution
consistent with the observed moments (note that because
s2i = si , 〈si〉 = 〈s2i 〉 all first moments are included) [8,17]. The
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resulting probability distribution takes the form
P (s) = Z−1 exp[−E(s)],
(1)
E(s) =
L∑
i<j
Jij sisj +
L∑
i=1
hisi,
where Z is the partition function. The parameters {Jij }, {hi}
must be chosen such that the distribution P (s) reproduces
the observed moments 〈sisj 〉. Here the {Jij } can be thought
of as capturing direct interactions between sites, disentan-
gled from the network of correlations that include indirect
effects mediated through intermediate sites [18–20]. Similar
maximum entropy approaches have been fruitfully applied
to analyze patterns of neural activity and predict contact
residues in protein families [19–22]. The description of the
selective cluster expansion algorithm used to infer E(s) is
given in [18,23]. Although only the pair correlations are
constrained in Eq. (1), the inferred Ising model accurately
predicts higher order correlations as well.
The form of the probability distribution gives rise to
the notion of a “prevalence landscape” that expresses the
relative frequencies of protease sequences. Previous work
has shown that the inferred prevalences of sequences from
HIV Gag proteins correlate with their replicative capacities,
another proxy for fitness [8,24], in line with the intuition that
fitter strains should be more prevalent. However, prevalence
is affected by many factors other than fitness, including
epidemiological dynamics, recombination, and demographic
noise, which complicate this association [25–27].
Insight into the relation between fitness and prevalence can
be obtained through Eigen’s model of evolution [13]. This
model assumes an infinite population of viruses and accounts
for mutation and selection, but neglects many of the important
effects described above. However, these simplifications allow
for the relationship between fitness and prevalence to be
studied using methods adopted from statistical physics [14,15].
Following Eigen’s model, the prevalence can also be written
as the outcome of evolutionary dynamics over a large number
of generations T , represented as a series of coupled Ising spin
systems [14],
e−E(s
T ) ∝
∑
{st }T−1t=1
exp
{
T −1∑
t=1
[K(2st − 1)(2st+1 − 1) − F (st )]
}
,
(2)
F (s) =
L∑
i<j
J
f
ij sisj +
L∑
i=1
h
f
i si,
where K is related to the per site per generation mutation rate
μ by K = 12 ln( 1−μμ ). Here F (s) is minus the log fitness of
sequence s and is referred to as the fitness landscape. The
superscripts t ∈ {1,2 . . . ,T } on the sequence vectors refer to
discrete generations. The superscript f on the parameters {hfi }
and {J fij } indicates that these parameters are taken from the
fitness landscape in Eq. (2) [assumed to have the same func-
tional form as Eq. (1)], rather than the prevalence landscape of
Eq. (1). The evolutionary dynamics described here applies to
evolution within a population of hosts. Equations describing
within host evolution would require accounting for differing
immune pressure between individuals [15], though protease
is not comparatively immunogenic [28]. Given that tens of
millions of humans have been infected with HIV over the
course of the epidemic and that both the number of infected
cells and their rate of turnover are high [29], the limit of large
population size and long sampling times that we consider here
is not unreasonable.
Ideally, one would like to invert Eq. (2) to solve for F (s)
in terms of E(s), because E(s) is inferred directly from
data. In principle, this could be achieved by matching the
distribution of sequences at the final generation T in the Ising
representation of Eigen’s model with the prevalence landscape,
given by Eq. (1). This is a challenging problem in general;
however, approximate results can be obtained by studying
a two site system, which can be solved by straightforward
transfer matrix methods. While network effects influence the
inferred couplings between sites, this simple approximation
provides useful intuition. Furthermore, network effects exert
a weaker influence on the 〈si〉, as most of their variance is
explained by the single site hi in Eq. (1).
Solving the two site version of Eq. (2) shows that the hf
are difficult to reliably infer, because the mutation coupling
K is large enough (K  − ln(μ) and μ  O(10−4), using
the microscopic mutation rate [30]) that very small hf lead
to large h in the prevalence landscape (see Appendix B for
further details). However, large values of J in the prevalence
landscape have a simple interpretation in the fitness landscape
as couplings between pairs of sites where mutating both sites
leads to only a small change in fitness compared to wild
type (Fig. 1). In this case the double mutant could become
advantageous with only a small increase in the fitness of one
hf1 + hf2
FIG. 1. The coupling −J between a pair of sites increases sharply
as the fitness of the double mutant approaches the fitness of the wild
type sequence. (a) The peak in −J occurs at the level crossing, where
−J f = hf1 + hf2 . If −J f becomes larger than hf1 + hf2 , so that the
double mutant has higher fitness than the wild type sequence (shaded
region), the corresponding coupling −J in the prevalence landscape
decreases. (b) Log fitness of the wild type strain and the double
mutant strain as a function of J f . The log fitnesses intersect at the
point where −J is maximized.
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FIG. 2. Stronger couplings are more likely to link sites of major resistance mutations. Here we show the network of interactions between
the top r ranked sites, from r = 40 (left) to r = 10 (right). Only the strongest couplings, those meeting or exceeding the largest coupling for
the lowest ranked site, are displayed. Interactions linking at least one major resistance site are darkly shaded; links between nonresistance sites
are lightly shaded.
of the mutations, as might occur when drugs are added to the
environment, for example. Mathematically, this occurs as −J f
approaches hf1 + hf2 . We refer to the point in parameter space
where the coupling between sites allows the double mutant
strain to have equal fitness to the wild type as a level crossing.
III. RESISTANCE MUTATIONS IN PROTEASE
To go from the interpretation of large values of −J in the
prevalence landscape as indicators of nearby level crossings
to predictions of resistance mutations requires elucidating a
relationship between level crossings and resistance mutations.
A rigorous argument relating resistance mutations to the
fitness landscape would require detailed knowledge of the
drug, its binding sites, the structure of the target protein,
and other details. However, generically we expect that when
the environment in which HIV replicates changes due to the
initiation of drug therapy, HIV must mutate in ways that
abrogate drug binding, while at the same time preserving
protein function. Large couplings −J connect sites that are
likely to be able to comutate with limited costs to fitness, even if
the associated individual mutations are costly. Such sets of sites
are therefore more likely to be associated with resistance. Here
our assumption is that resistance cannot be achieved through
selectively neutral mutations at single sites, in which case drug
treatment would likely be ineffective. Indeed, this appears to be
the typical case for HIV protease, where resistance mutations
are usually deleterious [31].
To predict the sites of resistance mutations based on the
above considerations, we consider the strongest couplings
−Jij associated with each site i. Using the largest coupling
values we then assign each site a rank r ∈ {1, . . . ,99} from
strongest to weakest. We predict that the sites with the strongest
interactions (i.e., the highest ranked sites) are most likely to
be associated with drug resistance. Focusing on the highest
ranked sites and the strong couplings between them can be
seen as a process of pruning weaker interactions from the
network. Three pruned versions of the network of mutational
interactions in HIV protease are shown in Fig. 2. However, note
that without any drug-specific information, we cannot specify
which sites in a strongly coupled pair should be associated
with resistance.
This model can be cast in the form of a classification rule by
predicting sites ranked at or above some threshold rank r to be
sites of drug resistance mutations and sites of lower rank to be
unassociated with resistance. To test the model’s performance,
we take the set of resistance sites to be those classified as
sites of major resistance mutations by the Stanford HIV drug
resistance database (sites 30, 32, 33, 46, 47, 48, 50, 54, 76, 82,
84, 88, and 90) [16]. As higher ranked sites are selected, the
proportion of sites that are associated with resistance should
increase. This can be measured using positive prediction value
(PPV) and negative prediction value (NPV), defined as
P (true = resistance|predicted = resistance),
P (true = non-resistance|predicted = nonresistance).
These are shown in Fig. 3 compared to benchmarks for a
random classifier and demonstrate that the performance of the
classification rule is substantially better than chance for higher
ranked sites. Examination of the true positive rate (TPR) and
false positive rate (FPR),
P (predicted = resistance|true = resistance) ,
P (predicted = resistance|true = nonresistance) ,
shown in Fig. 3, confirm that TPR > FPR, indicating perfor-
mance better than chance. We also note that the fraction of
the strongest interactions which link at least one major drug
resistance site is extremely high, as can be seen in Fig. 2
(further details in Appendix D).
To examine these results using classical statistical signif-
icance testing, we used the hypergeometric distribution to
compute p values for the null model of randomly selecting
the number of sites at or above each rank threshold and
obtaining at least as many resistance mutations as found using
the ranking classifier (see Appendix C ). The predictions
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FIG. 3. Top-ranked sites, based on the maximum strength of their
couplings, are far more likely to be sites of major drug resistance
mutations than would be expected by chance. (a) Negative prediction
value (NPV, upper curves) and positive prediction value (PPV, lower
curves) for the classifier compared to the benchmark of random
guessing as functions of rank. Collections of the highest ranked sites
are clearly associated with improved PPV. (b) False positive rate
(FPR) and true positive rate (TPR) as functions of rank. TPR > FPR
indicates performance better than chance.
have p values < 0.05 for essentially all rank thresholds from
r = 3–50, which comports with the argument that strongly
coupled sites are more likely to be sites of resistance mutations
and supports the significance of the predictions of resistance
among higher ranked sites. The lack of significance for
the highest ranked pair is a consequence of the very small
number of sites. Further tests also show a significant difference
between the rank of resistance sites versus nonresistance
sites (Mann-Whitney U = 343, p = 0.0255), another way to
test the utility of interactions in predicting resistance sites.
We also tested related classification rules constructed using
direct information [19] and correlation matrices, with no
improvement in performance. All methods based on pairwise
interactions outperformed methods ranking sites according to
their mutability, an intuitive result given that most resistance
mutations in protease are deleterious (see Appendix D for
details).
IV. DRUG COMBINATIONS AND BIOPHYSICAL
INFORMATION
As virological failure occurs in patients undergoing treat-
ment with protease inhibitors, new protease inhibitor drugs
are administered [2]. To further assess the validity of our
predictions, we used the model to infer pairs of protease
inhibitors where multidrug resistance should be unlikely to
evolve. We reasoned that resistance should be less likely if (1)
a pair of drugs share few resistance mutations in common and
if (2) fitness constraints make it difficult for the virus to tolerate
mutations conferring resistance for both drugs simultaneously.
The first condition can easily be checked by simply counting
the number of common resistance mutations for each pair
of drugs (see [16]). Information about the second condition
can be obtained through the inferred couplings in our model.
In the same way that large negative values of J indicate
sites that can readily mutate together, positive values of J
indicate sites where double mutations are suppressed. Thus, the
interactions between the resistance mutations that are common
to both drugs should be as positive as possible. We found three
combinations (atazanivir-indinavir, atazanavir-fosamprenavir,
and darunavir-nelfanavir) that are optimal for both of these
criteria in the Pareto sense: Improvement in one criterion
necessitates a reduction in the other criterion. Two of these,
along with both near-optimal pairs (atazanavir-darunavir and
atazanavir-lopinavir), incorporate atazanavir, consistent with
clinical knowledge that the resistance profile of atazanavir
appears distinct from other protease inhibitors [32].
The network of large interactions also captures important
biophysical information. As a first example, the third strongest
coupling is between sites 82 and 54. Site 82 is frequently
the first resistance mutation site observed after the initiation
of protease inhibitor treatment and is usually followed by
mutation at site 54 [1]. Some couplings may also be associated
with stabilizing mutations, which compensate for loss of
fitness due to a destabilizing mutation. A recent biophysical
study examined the melting temperatures of HIV protease with
a major resistance mutation at site 84 [31]. The study showed
that, on its own, the major resistance mutation reduced the
stability of HIV protease considerably. When the mutation at
site 84 is accompanied by one of a set of three known accessory
mutations at sites 10, 63, and 71, stability is restored, or even
enhanced. Couplings between sites 10 and 84, and sites 63 and
84, are strong, in the top 7% of all couplings (though weaker
than the couplings shown in Fig. 2, which are within the top
1%). The coupling between sites 71 and 84 is slightly weaker,
but still in the top 13% of all couplings. This suggests that
links between destabilizing mutations and those that improve
protein stability may be captured by the network of interactions
inferred from sequence data.
V. CONCLUSIONS
Our results show that from sequence information alone,
much of the evolutionary response of HIV protease to
inhibitors can be reproduced. While in the case of protease
inhibitors, the answer was known, the successful retrodictions
indicate that our understanding of HIV evolution is becoming
predictive at the level of individual residue sites. We anticipate
that the methods developed above will contribute to the
development of predictive theories of viral evolution and
to the development of new treatments, such as integrase
inhibitors [33], where resistance is not nearly as well char-
acterized as in protease.
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APPENDIX A: SEQUENCE DATA AND CORRELATIONS
We downloaded a multiple sequence alignment (MSA) for
the HIV-1 clade B protease protein from the Los Alamos
National Laboratory HIV database (http://www.hiv.lanl.gov).
Sequences labeled by the database as “problematic” were
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FIG. 4. (a) Plot of h versus hf showing the sensitivity of h. The inferred field h approaches a μ-dependent cutoff as hf → ∞. (b) Plot of
inferred h and J as a function of Jf for a two site approximation assuming hf1 = hf2 = 0.1. The inferred value of h is insensitive to Jf until
the “level crossing” point hf1 + hf2 + J f = 0 is reached. (c) Similar results are obtained when hf1 and hf2 are not identical. Here hf1 = 0.1 and
h
f
2 = 0.05.
excluded. To minimize evolved drug resistance [3,34], we only
selected sequences obtained in the year 1996 or earlier, and we
removed sequences from trial studies of protease inhibitors, as
described in the main text, yielding a total of 6701 sequences
from 757 unique patients. After downloading, the MSA data
was processed to remove insertions relative to the HXB2
reference sequence [35]. Ambiguous amino acids were then
imputed with simple mean imputation.
The binarized MSA data consists of sequences from B
patients, which we label k = 1, . . . ,B. Let us call the number
of sequences from the kth patient as Bk , and let us write the
ath sequence from patient k as s(k,a) = {s(k,a)1 , . . . ,s(k,a)99 }, with
the single site variables si ∈ {0,1}. To obtain a representative
sample of the population, we averaged over multiple sequences
from the same patient, so the one- and two-point correlations
we obtain from the data are then
pi = 1
B
B∑
k=1
[
1
Bk
Bk∑
a=1
s
(k,a)
i
]
,
pij = 1
B
B∑
k=1
[
1
Bk
Bk∑
a=1
s
(k,a)
i s
(k,a)
j
]
. (A1)
The one-point correlations pi measure the frequency of
mutations at each position i, and the two-point correlations
pij measure the frequency of pairs of mutations occurring
simultaneously at two positions i, j .
APPENDIX B: RELATIONSHIP BETWEEN h f ,J f AND h,J
In general, it is difficult to show the precise relationship be-
tween the underlying hf ,Jf parameters and the corresponding
inferred h,J . However, some insight can be obtained in simple
cases.
First, let us consider a single site approximation in the Eigen
model in Ising form [14]. Here the formula for exp [−E(sT )]
is as in (2), but with F (s) given by
F (s) =
L∑
i=0
h
f
i si . (B1)
We can solve for each site by decomposing the sum in (2) into
a product of transfer matrices,
M =
(
exp
(
K − hf ) exp (−K)
exp (−K − hf ) exp (K)
)
. (B2)
In the limit of many generations, we can rewrite (2) as
exp[−E(sT )] ∝ lim
T →∞
MT v0, (B3)
where v0 is a vector with the proportion of the population
initially in the wild type and mutant states. This implies that
we can obtain all of the information about the asymptotic
state by looking at the eigenvector associated with the largest
eigenvalue of M . Solving for the corresponding field yields
h = − ln
⎡
⎣(1 − ehf
2
)
e2K +
√
ehf +
(
1 − ehf
2
)2
e4K
⎤
⎦ .
(B4)
We find then that h is highly sensitive to small changes
in hf for small hf [see Fig. 4(a); note that K  4 for
amino acid mutations in HIV]. Precisely inferring hf from
h is thus a difficult problem in practice. However, it is
likely that these issues are moderated at population sizes that
are finite. Expressions for h,J inferred through a two-site
approximation are unwieldy, but can easily be evaluated
numerically [Figs. 4(b) and 4(c)].
To compute the solution for the Eigen model in the two site
approximation, the following transfer matrix was used:
M =
⎛
⎜⎜⎜⎝
exp
(
2K − hf1 − hf2 − J
)
exp
(− hf1 ) exp (− hf2 ) exp (−2K)
exp
(− hf1 − hf2 − J ) exp (2K − hf1 ) exp (− 2K − hf2 ) 1
exp
(− hf1 − hf2 − J ) exp (− 2K − hf1 ) exp (2K − hf2 ) 1
exp
(− 2K − hf1 − hf2 − J ) exp (− hf1 ) exp (− hf2 ) exp (2K)
⎞
⎟⎟⎟⎠. (B5)
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FIG. 5. Minus log p values (base 10) as a function of rank. The
solid line indicates the standard significance threshold 0.05.
The normalized elements of the eigenvector associated with the
largest eigenvalue give the fraction of the population in each
state and are trivially algebraically related to the parameters of
the prevalence landscape.
APPENDIX C: STATISTICAL SIGNIFICANCE OF
RESISTANCE MUTATION DETECTION
As a further check of the significance of the results, we
computed p values for the null hypothesis that predicted
resistance sites were drawn randomly. This results in a p value
that is a function of number of predicted resistance sites. If
there are r sites randomly drawn out of a total of N = 99 sites,
and m of the sites drawn are resistance sites (out of M = 13),
the p value is given by
p =
M∑
k=m
(
M
k
)(
N−M
r−k
)
(
N
r
) . (C1)
FIG. 6. Comparison of classification results for PPV.
FIG. 7. Comparison of direct information approach and the direct
interaction approach from the paper to classifying drug resistance
mutations using PPV.
The p values are plotted in Fig. 5 as a function of rank r . As
noted in the main text, p < 0.05 for almost all ranks between
3 and 50, supporting the significance of the results, as the
classification rule is not expected to perform well for weakly
coupled sites (low ranks).
APPENDIX D: RESULTS FOR ALTERNATIVE
CLASSIFICATION PROCEDURES AND
DRUG-NAIVE DATA
Here we show predictions of resistance sites using al-
ternative classification rules and data. We first examine the
predictions made with the same model, but including all
sequences from drug-naive patients up until the present.
The results are shown in Fig. 6, along with the calculation
from the main text for comparison, and are not significantly
FIG. 8. Negative predictive value (NPV, upper curves) and posi-
tive predictive value (PPV, lower curves) for sites ranked according
to the frequency of mutations at that site.
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FIG. 9. Negative predictive value (NPV, upper curves) and
positive predictive value (PPV, lower curves) for sites ranked
according to the inferred field at that site.
different. This is probably because transmitted protease
inhibitor resistance is relatively rare [3,34]. However, the
performance is slightly better at the extremely high threshold
limit for the drug-naive sequence case, a possible signature of
transmitted drug resistance.
Another very simple way to make predictions is to simply
threshold the observed correlation matrix, defined by
Cij = 〈sisj 〉 − 〈si〉〈sj 〉√〈si〉(1 − 〈si〉)〈sj 〉(1 − 〈sj 〉) . (D1)
In principle, all of the arguments developed in the main text
apply to correlations as well. However, the presumed advan-
tage of the direct interactions approach is that it disentangles
indirect from direct interactions, which the correlation matrix
does not. Predictions using the correlation matrix compared
with the direct interactions approach (with all sequences from
drug-naive patients, as well as the restricted sequence set used
in the main text) are in Fig. 6. The direct interaction approach
clearly performs better for the high ranked sites.
In protein contact prediction, a common measure of
interactions is the direct information. Direct information is
defined with respect to a two site model:
P (si,sj ) = Z−1 exp (Jij sisj + ˜hisi + ˜hj si). (D2)
The coupling Jij is taken from the full solution of the inverse
Ising problem with all sites, and the fields ˜hi and ˜hj are chosen
FIG. 10. Performance on the classification problem of identifying
pairs of sites where one or more sites are associated with major drug
resistance using the top 30 ranked couplings, measured by positive
predictive value (PPV).
to match the single site probabilities P (si) and P (sj ). The
direct information between sites i and j is then constructed as
DIij =
∑
si ,sj
P (si,sj ) ln
[
P (si,sj )
P (si)P (sj )
]
. (D3)
Thresholding the direct information matrix and following the
usual procedure results in predictions of resistance sites. The
results are shown in Fig. 7.
All methods based on interactions perform better than
ranking sites according to their mutability, either directly
by mutation frequency (Fig. 8) or by the inferred field h
(Fig. 9). This is because mutations in protease that confer drug
resistance in protease tend to be deleterious; thus, directly
ranking sites according to the ease of single mutations leads
to poor predictions of resistance.
We note also that many of the largest couplings link sites
where just one site is classified as a major site of drug
resistance. Based on the methods presented here, we have
no way to distinguish which site or sites in a strongly linked
pair should be associated with drug resistance. One alternate
approach, then, would be to rank the couplings in order of their
strength and attempt to predict how often either one or both
coupled sites are sites of major drug resistance. Performance
on this classification problem is also substantially better than
random for the largest couplings, as shown in Fig. 10.
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